SEM Q1 Earnings Call: Regulatory Headwinds and Mixed Division Performance Shape Outlook
Healthcare services company Select Medical (NYSE:SEM) missed Wall Street's revenue expectations in Q1 CY2025 as sales rose 2.4% year on year to $1.35 billion. The company's full-year revenue guidance of $5.4 billion at the midpoint came in 1.6% below analysts' estimates. Its GAAP profit of $0.44 per share was 7.3% below analysts' consensus estimates.
Is now the time to buy SEM? Find out in our full research report (it's free).
Revenue: $1.35 billion vs analyst estimates of $1.39 billion (2.4% year-on-year growth, 2.6% miss)
EPS (GAAP): $0.44 vs analyst expectations of $0.47 (7.3% miss)
Adjusted EBITDA: $151.4 million vs analyst estimates of $166.5 million (11.2% margin, 9.1% miss)
The company dropped its revenue guidance for the full year to $5.4 billion at the midpoint from $5.5 billion, a 1.8% decrease
EPS (GAAP) guidance for the full year is $1.14 at the midpoint, beating analyst estimates by 1.8%
EBITDA guidance for the full year is $520 million at the midpoint, below analyst estimates of $531.3 million
Operating Margin: 8.3%, in line with the same quarter last year
Free Cash Flow was -$55.8 million compared to -$119.2 million in the same quarter last year
Sales Volumes fell 1.9% year on year (1% in the same quarter last year)
Market Capitalization: $1.96 billion
Select Medical's first quarter results reflected the company's ongoing transition following the Concentra spin, with divergent trends across its main business lines. Management attributed the quarter's performance to robust growth in the inpatient rehabilitation division, which offset challenges in both outpatient and critical illness recovery hospital operations. CEO Robert Ortenzio cited severe weather events and Medicare reimbursement reductions as primary pressures on outpatient results, while regulatory changes and a delayed flu season weighed on the critical illness recovery segment.
Looking ahead, management's guidance is shaped by ongoing regulatory uncertainty and shifting payer dynamics. The team expressed cautious optimism about inpatient rehabilitation expansion, noting a strong development pipeline and recent facility openings. However, they acknowledged persistent headwinds in the critical illness recovery segment, including higher outlier thresholds and the impact of the 20% transmittal rule. Management stated, "We are constantly having conversations both on the regulatory side with the new CMS administration and on the legislative side," underscoring the unpredictable reimbursement environment.
Select Medical's leadership focused on the mixed performance across its divisions and the external factors impacting results. Management highlighted division-specific drivers and detailed ongoing initiatives to mitigate recent headwinds and support future growth.
Inpatient Rehab Outperformance: The inpatient rehabilitation division delivered double-digit revenue and EBITDA growth, supported by both increased daily rates and a robust pipeline of new facility openings and expansions. Management pointed to occupancy rates above 80% in mature hospitals and a multi-year plan to add 440 new beds.
Regulatory Headwinds in Critical Illness Recovery: The critical illness recovery hospital segment faced regulatory challenges, particularly a sharp increase in the high cost outlier threshold and the 20% transmittal rule. Management estimated these changes accounted for two-thirds of the EBITDA decline for this segment, and noted ongoing discussions with the Centers for Medicare & Medicaid Services (CMS) to address these impacts.
Outpatient Division Weather Disruption: Severe winter storms in key geographies and a 3% decline in Medicare reimbursement led to lower outpatient volumes and EBITDA. The division saw a late-quarter recovery, and management expects further improvements as technology and access initiatives progress.
Technology and Margin Initiatives: Management emphasized ongoing investments in technology for the outpatient business, including a new software platform aimed at improving productivity and contract negotiations. Early benefits were observed, and management expects margin improvement as further releases are implemented.
Strategic Capacity Management: The company continued to optimize its outpatient footprint by opening 10 new clinics and closing or consolidating 13 underperforming locations, aligning resources with market demand and supporting more efficient operations.
Management's outlook for the remainder of the year centers on regulatory and reimbursement trends, the pace of rehab expansion, and operational improvements in challenged segments.
Regulatory Uncertainty Remains: The company's earnings trajectory will depend on future CMS policy changes impacting critical illness recovery reimbursement, as well as ongoing advocacy to mitigate outlier threshold increases and transmittal rule effects.
Rehabilitation Expansion Pipeline: A strong pipeline of new inpatient rehab facilities and bed additions is expected to drive segment growth, with management noting both signed projects and additional opportunities under evaluation.
Margin Recovery Initiatives: Continued implementation of technology upgrades and productivity measures in the outpatient division are expected to support gradual margin improvement, although external factors such as weather and Medicare rates remain risks.
Justin Bowers (Deutsche Bank): Asked about expected occupancy rates in new inpatient rehab facilities. Management guided for occupancy to remain above 85% in mature hospitals, even as new capacity comes online.
Ben Hendrix (RBC Capital Markets): Inquired about mitigation strategies for regulatory headwinds in critical illness recovery hospitals. Management indicated active discussions with CMS and ongoing advocacy, but cautioned that policy changes may take time.
William Sutherland (The Benchmark Company): Sought clarification on the magnitude and timing of high cost outlier impacts and start-up costs. Management confirmed that start-up losses remained consistent year over year, with most headwinds concentrated in the first six weeks of the quarter.
William Sutherland (The Benchmark Company): Asked about outpatient margin improvement initiatives. Management described new technology rollouts and improved commercial contract rates as key drivers, with incremental benefits expected throughout the year.
Anne Hines (Mizuho): Asked about potential acceleration in inpatient rehab expansion to diversify away from critical illness recovery. Management confirmed an acceleration beyond currently announced projects, citing a robust project pipeline and ongoing market evaluations.
In the coming quarters, the StockStory team will monitor (1) regulatory developments and any CMS decisions related to reimbursement for critical illness recovery, (2) progress on opening new inpatient rehab facilities and the pace at which they reach targeted occupancy, and (3) the effectiveness of technology and operational initiatives aimed at restoring outpatient division margins. Additionally, trends in patient volumes and reimbursement rates across all segments will remain key indicators of business momentum.
Select Medical currently trades at a forward P/E ratio of 13×. Should you double down or take your chips? See for yourself in our free research report.
The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Black America Web
an hour ago
- Black America Web
Social Security Projected To 'Go-Broke' Earlier Than Expected
Source: filo / Getty I'm 32, and for as long as I can remember, I've heard about how Social Security was on its way to being depleted. It's been a known issue, yet there's been no meaningful legislation to address it. As a result, rising health costs and recent legislation have led to the projected 'go-broke' date moving up for both Social Security and Medicare. According to AP, an annual report released on Wednesday projects the go-broke date for the Social Security trust will occur in 2034, a year up from last year's projection of 2035. For Medicare, the new date was a bit more drastic, going up from 2036 to 2033. Now, to be clear, the go-broke date doesn't mean benefits will be stopped outright. It simply means payouts will be given at a reduced rate. For Social Security, it's estimated that benefit payouts would be capped at 81 percent, and for Medicare, the government provided health insurance that covers people age 65 and older, it's estimated that payments would only cover 89 percent of costs for patients' hospital visits, hospice care, and nursing home stays. This reduction would significantly affect the 68 million Americans currently enrolled in Medicare, The Social Security and Medicare trust funds are overseen by four trustees. The Treasury Secretary serves as managing trustee, with the Secretaries of Labor, Health and Human Services, and the Commissioner of Social Security being the other three. The trustee board technically has two other presidentially-appointed and Senate-confirmed trustees who serve as public representatives, but those roles have been empty for over a decade. 'Current-law projections indicate that Medicare still faces a substantial financial shortfall that needs to be addressed with further legislation. Such legislation should be enacted sooner rather than later to minimize the impact on beneficiaries, providers, and taxpayers,' the trustees state in the report. The go-broke date for Social Security has fluctuated quite a bit in recent years, with annual reports from recent years projecting 'go-broke' dates in 2026, 2028, and 2031, respectively. A poll conducted by AP last month revealed that 3 in 10 Americans over 60 are not confident that Social Security benefits would be there for them if they needed them. Clearly, this news won't do much to increase their confidence. Social Security Administration Commissioner Frank Bisignano, who was only sworn into his role last month, released a statement saying that 'the financial status of the trust funds remains a top priority for the Trump Administration.' This seems like another instance of the Trump administration being all talk, little action, as there seems to be very little meaningful legislation to address the issue. In fact, Trump's 'Big, Beautiful' budget bill has very little in the way of relief for Social Security and Medicare. As a millennial with very little faith in America's ability to improve upon itself, I would very much like it if I could opt out of paying Social Security because while I'm not over 60, I have very little faith that the benefits are going to be there for me by the time I can use them. Heck, at the rate we're going, I'd honestly just be happy if we even have a functional democracy at that point. SEE ALSO: Trump's 'Big, Beautiful Bill' Will Destroy Medicare, Food Stamps Student Loan Collections Make American Credit Scores Plummet SEE ALSO Social Security Projected To 'Go-Broke' Earlier Than Expected was originally published on Black America Web Featured Video CLOSE
Business Insider
4 hours ago
- Business Insider
Coterra Energy (CTRA) Receives a Buy from Wells Fargo
Wells Fargo analyst Roger Read maintained a Buy rating on Coterra Energy (CTRA – Research Report) on June 20 and set a price target of $31.00. The company's shares closed last Friday at $26.97. Confident Investing Starts Here: According to TipRanks, Read is a 3-star analyst with an average return of 1.7% and a 53.80% success rate. Read covers the Energy sector, focusing on stocks such as Valero Energy, EOG Resources, and Phillips 66. In addition to Wells Fargo, Coterra Energy also received a Buy from Piper Sandler's Mark Lear in a report issued on June 16. However, on June 9, Morgan Stanley maintained a Hold rating on Coterra Energy (NYSE: CTRA). Based on Coterra Energy's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $924 million and a net profit of $516 million. In comparison, last year the company earned a revenue of $1.37 billion and had a net profit of $352 million Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CTRA in relation to earlier this year. Last month, Stephen Bell, the EVP – Business Development of CTRA sold 100,000.00 shares for a total of $2,525,000.00.
Forbes
4 hours ago
- Forbes
Price Controls On Doctors Are Costing Patients Dearly
Market Manipulation Just like the December 2024 continuing resolution, the current budget reconciliation bill fails to address the problem of Medicare reimbursing physicians at below market rates. Without a fix, the inevitable consequences will be worsening doctor shortages, declining healthcare quality, higher overall healthcare spending, and the accelerated loss of independent practices. Of course, how do we know that Medicare's payments to doctors are below their economic value? To start, Medicare's reimbursement rates have declined relative to both the cost of running a medical practice and inflation. Doctors consistently report that they lose money treating Medicare patients. A survey of doctors found that Medicare's low reimbursement rates (68%) are a primary threat to independent practices. As for inflation, it has grown 34.5% overall since January 2016 while the prices received by doctors have grown less than half as much - just 15.1%. This is not due to demand for healthcare declining – remember the huge number of aging Baby Boomers seeking health care – or a huge surge in the number of qualified doctors serving patients. In fact, the level of doctors serving patients today - 25.4 active physicians per 10,000 residents - is down from 2019 and has fallen back to 2009 levels. The problem is government setting prices at below market levels. And setting prices below market rates cause adverse consequences to our health, such as fewer doctors available to serve patients. This creates serious health risks for patients including longer wait times for appointments, less access to specialty care, shorter doctor visits, larger numbers of medical errors, and more misdiagnoses or missed diagnoses. These risks are more acute for people living in rural areas, who have a higher chance of living in areas deemed 'medical deserts' or regions that lack sufficient access to pharmacies, primary care providers, and hospitals. Medicare's uneconomical reimbursement system is also changing how patient care is delivered. For example, under the current reimbursement system, Medicare compensates hospitals more than independent physician offices for performing the same service. This incentivizes independent practices to merge with hospitals. Consolidating lower-cost physician practices into higher-cost hospital systems is driving up overall healthcare costs for patients and taxpayers and is reducing patient choice. Congress has acknowledged that there are serious consequences from government price controls, enacting legislation to raise provider payments by 2.9% for most of 2024. But these payments went back down on January 1, and the problem continues to plague the healthcare system. Fixing Medicare's flawed reimbursement policy should be a top priority for Congress. The more efficient reform comprehensively addresses Medicare's broader deficiencies by turning Medicare into a cash-based benefit system that funds health savings accounts (HSAs) for seniors. This direct payment option allows beneficiaries to receive their Medicare benefits in the same manner that they receive their Social Security benefits. At current spending levels, Medicare could give each beneficiary $15,150 annually to cover their insurance and healthcare costs. Under this system, patients and physicians, not bureaucrats, would take change and prices would reflect value. Providers would have to compete and would be incentivized to find new and better ways to expand value and reducing costs for patients. Fundamental reforms that establish well-functioning healthcare and health insurance markets will take time. Given this, Congress could act more immediately to index government payments to medical inflation and stop paying different reimbursement rates for the same services depending on where care is delivered. With more people aging, taxpayers will be spending more and more for Medicare and Medicaid. Unless Congress acts soon to stop Medicare's underpayment of physicians, it is patients who will ultimately pay the highest price with less access to doctors and specialists and longer wait times for life-saving care.
